Adenoviral vector-mediated XXXX gene therapy for @entity263 .

@entity263 @entity19 @entity5 @entity899 @entity3 @entity35 @entity72624
We previously identified the @entity19 @entity72624 ( @entity72624 ; related to testes-specific, vespid, and pathogenesis proteins) gene as a direct target of @entity899 with proapoptotic activities in various @entity5 cell lines, including @entity263 . To test the therapeutic potential of @entity72624 we constructed an adenoviral vector capable of efficient transduction and expression of @entity72624 (AdmRTVP-1) and used this vector in an orthotopic, metastatic @entity19 model of @entity263 . A single intratumoral administration of AdmRTVP-1 gene therapy significantly reduced @entity5 wet weight compared with control Adbetagal-injected @entity5 at two time points after injection with two different vector doses (p < or = 0.01 at 7 and 14 days). Spontaneous @entity3 to lung was also significantly reduced (p < or = 0.02). Evaluation of treated @entity5 revealed increased apoptosis and lower microvessel density counts. In a @entity35 aortic ring sprouting assay, AdmRTVP-1 inhibited endothelial cell sprouting compared with Adbetagal, confirming its antiangiogenic activity. These therapeutic activities were associated with a significant increase in survival from 22.9 to 26.8 days (p = 0.003) in this @entity263 . Interestingly, there were significant increases in the infiltration of @entity5 -associated macrophages, dendritic cells, and CD8+ T cells, which persisted at 14 days posttreatment in the AdmRTVP-1-treated @entity5 compared with @entity5 . In addition, significantly increased natural killer and cytotoxic T lymphocyte activities were demonstrated in the @entity19 with AdmRTVP-1-treated @entity5 . The unique therapeutic properties of AdmRTVP-1 gene therapy demonstrated in this study provide new opportunities for gene and immunotherapy of @entity263 and potentially other @entity5 .
